Ulcerative Colitis

IBD patients were less likely to have diets that regularly include vegetables, cereals, breads, and diary.

There was no association found between migraines and Crohn’s disease or ulcerative colitis.

The company expects to continue to study the potential inflammatory bowel disease treatment.

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

96.4% of patients in symptomatic remission at week 152 were corticosteroid-free.

Telemedicine could be useful if it is added to regimen of in-person health care visits.

The treatment resulted in a significant reduction in expression of genes representing T & B lymphocytes, plasma cells/plasmablasts, and myeloid cells.

Researchers found no difference between the risk of death or mechanical ventilation based on different IBD Treatments.

It could take up to 10 years to develop new treatments for inflammatory bowel disease.

Many gastroenterologists have utilized telemedicine during the ongoing COVID-19 pandemic.

Both the Mediterranean Diet and the Specific Carbohydrate diet achieved nearly 50% symptomatic remission in patients with IBD.

Small molecule treatments have been historically effective at treating IBD.

More than half of the patients in the study were treated for inflammatory bowel disease with infliximab.

The UNITI studies have shown ustekinumab is effective at inducing and maintaining clinical remission in Crohn’s disease patients.

Vedolizumab treatment was associated with lower IMC recurrence rate after ICI resumption.

More patients treated with risankizumab 360 mg achieved clinical remission than the induction-only control group.

Patients treated with ustekinumab had significantly more prior biologic use than patients treated with vedolizumab.

The treatment is also being studied for safety and efficacy in patients with Crohn’s disease.

Nearly two-thirds of patients had improved or resolved EIM after ustekinumab treatment.

Most of the data on vedolizumab has been limited by small sample sizes and short follow-up.

Infections in patients with ulcerative colitis treated with ozanimod were mostly characterized as non-serious.

Ulcerative colitis patients with fatigue are more likely to be unemployed, have moderate or severe disease, and higher Mayo scores.

Hospitalizations were more likely in patients with CDI of small bowel and Crohn's disease, with worse outcomes noted in patients admitted to ICU.

The presence of extra-intestinal manifestations in biologic-naïve anti-TNF patients with Crohn’s disease was a predictor of disease severity.

Histologic scores in the endoscopically involved mucosa of index biopsies not linked to subsequent extension of ulcerative colitis.